|
[1]SIRTORI CR.The pharmacology of statins[J].Pharmacologica Res, 2014, 88 (9) :3-11.
|
|
[2]KEYSER CE, KOEHLER EM, SCHOUTEN JN, et al.Statin therapy is associated with a reduced risk of non-alcoholic fatty liver in overweight individuals[J].Dig Liver Dis, 2014, 46 (8) :720-725.
|
|
[3]YE J, WANG C, SUMPTER R, et al.Disruption of hepatitis C virus RNA replication through inhibition of hosprotein geranylgeranylation[J].Proc Natl Acad Sci USA, 2003, 100 (26) :15865-15870.
|
|
[4]COREY KE, KANE E, MUNROE C, et al.Hepatitis C virus infection and its clearance alter circulating lipids:implications for long-term follow-up[J].Hepatology, 2009, 50 (4) :103-107.
|
|
[5]ZHU Q, LI N, HAN Q, et al.Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C:a systematic review and meta-analysis[J].Antiviral Res, 2013, 98 (3) :373-379.
|
|
[6]KONDO C, ATSUKAWA M, TSUBOTA A, et al.An open-labe randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin[J].J Viral Hepat, 2012, 19 (9) :615-622.
|
|
[7]HARRISON SA, ROSSARO L, HU KQ, et al.Serum cholestero and statin use predict virological response to pegintereron and ribavirin therapy[J].Hepatology, 2010, 52 (3) :864-874.
|
|
[8]PRASHANT P, FADI R, OELURIND O.Sustained virologic response and other potential enotype-specific roles of statins among patients with hepatitis C-related chronic liver diseases[J].Clin Res Hepato Gastroenterol, 2015, 39 (5) :555-565.
|
|
[9]MOHANTY A, TATE J, GARCIA-TSAO G.Statins are Associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis[J].Gastroenterology, 2016, 150 (2) :430-440.
|
|
[10]SIMON T, BONILLA H, YAN P, et al.Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and HCC, among patients with HCV[J].Hepatology, 2016, 64 (1) :47-57.
|
|
[11]BADER T, KORBA B.Simvastatin potentiates the anti-hepatitis Bvirus activity of FDA-approved nucleoside analogue inhibitors in vitro[J].Antiviral Res, 2010, 86 (3) :241-245.
|
|
[12]TSAN YT, LEE CH, WANG JD, et al.Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection[J].J Clin Oncol, 2012, 30 (6) :623-630.
|
|
[13]CHEN CI, KUAN CF, FANG YA, et al.Cancer risk in HBV patients with statin and metformin use:a population-based cohor study[J].Medicine (Baltimore) , 2015, 94 (6) :e462.
|
|
[14]HUANG YW, LEE CL, YANG SS, et al.Statins Reduce the risk o cirrhosis and its decompensation in chronic hepatitis B patients:Anationwide cohort study[J].Am J Gastroenterol, 2016, 111 (7) :976-985.
|
|
[15]ALAEI-ANDABILI SH, ALAVIAN SM.Regulatory T cells are the most important determinant factor of hepatitis B infection prognosis:a systematic review and meta-analysis[J].Vaccine, 2012, 30 (38) :5595-5602.
|
|
[16]OKETANI M, IDO A, NAKAYAMA N, et al.Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan:summary of the annual nationwide survey between 2004 and 2009[J].Hepato Res, 2013, 43 (2) :97-105.
|
|
[17]GODSTEN MR, MASCITELLI L, PEZZETTA F.The double-edged sword of statin immunomodulation[J].Int J Cardiol, 2009, 135 (1) :128-130.
|
|
[18]WU DC.Hepatitis B virus reactivation associated with atorvastatin[J].Int J Cardiol, 2013, 17 (11) :e1069-e1070.
|
|
[19]MARRONE G, MAESO-DIAZ R, GARCIA-CADENA G, et al.KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers:behind the molecular mechanisms of statins[J].Gut, 2015, 64 (9) :1434-1443.
|
|
[20]VILLA E, CAMMA C, MARIETTA M, et al.Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis[J].Gastroenterology, 2012, 143 (5) :1253-1260.
|
|
[21]ANSTEE QM, WRIGHT M, GOLDIN R, et al.Parenchymal extinction:coagulation and hepatic fibrogenesis[J].Clin Liver Dis, 2009, 13 (1) :117-126.
|
|
[22]LOTSCH F, KONIGSBRUGGE O, POSCH F, et al.Statins are associated with low risk of venous thromboembolism in patients with cancer:a prospective and observational cohort study[J].Thromb Res, 2014, 134 (5) :1008-1013.
|
|
[23]SAHEBKAR A, SERBAN C, URSONIU S, et al.The impact of statin therapy on plasma levels of von Willebrand factor antigen.Systematic review and meta-analysis of randomised placebo-controlled trials[J].Thromb Haemost, 2016, 115 (3) :520-532.
|
|
[24]RAY K.Liver:Sussing out statins in cirrhosis-KLF2 is the key[J].Nat Rev Gastroenterol Hepatol, 2015, 12 (2) :64.
|
|
[25]MOTZKUS-FEAGANS C, PAKYZ AL, RATLIFF SM, et al.Statin use and infections in veterans with cirrhosis[J].Aliment Pharmacol Ther, 2013, 38 (6) :611-618.
|
|
[26]JANDA S, YOUNG A, FITZGERALD JM, et al.The effect of statins on mortality from severe infections and sepsis:a systematic review and meta-analysis[J].J Crit Care, 2010, 25 (4) :656, e7-e22.
|
|
[27]PATEL JM, SNAITH C, THICKETT DR, et al.Randomized doubleblind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial) [J].J Crit Care, 2012, 16 (6) :r231.
|
|
[28]KUMAR S, GRACE ND, QAMAR AA.Statin use in patients with cirrhosis:a retrospective cohort study[J].Dig Dis Sci, 2014, 59 (8) :1958-1965.
|
|
[29]CABRERA L, ABRALDES JG.Statins:the panacea of cirrhosis?[J].Curr Hepatol Rep, 2016, 15 (1) :1-7.
|
|
[30]ZAFRA C, ABRALDES JG, TURNES J, et al.Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis[J].Gastroenterology, 2004, 126 (3) :749-755.
|
|
[31]ABRALDER JG, ALBILLOS A, BANARES R, et al.Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension:a randomized controlled trial[J].Gastroenterology, 2009, 136 (5) :1651-1658.
|
|
[32]ABRALDES JG, VILLANUEVAL C, ARACIL C, et al.Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis[J].Gastroenterology, 2016, 150 (5) :1160-1170.
|
|
[33]AKOFERL B, LEPENNEC V, CHICHE L, et al.Hepatocellular cancer in the non-cirrhotic liver[J].J Visc Surg, 2011, 148 (1) :3-11.
|
|
[34]SINGH S, SINGH PP, ROBERT LR, et al.Chemopreventive strategies in hepatocellular carcinoma[J].Nat Rev Gastroenterol Hepatol, 2014, 11 (1) :45-54.
|
|
[35]SINGH S, SINGH PP, SINGH AG, et al.Statins are associated with a reduced risk of hepatocellular cancer:a systematic review and meta-analysis[J].Gastroenterology, 2013, 144 (2) :323-332.
|
|
[36]HSIANG JC, WONG GL, TSE YK, et al.Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population:a propensity score landmark analysis[J].JHepatol, 2015, 63 (5) :1190-1197.
|
|
[37]JEON CY, GOODMAN MT, COOK-WIENS G, et al.Statin use and survival with early-stage hepatocellular carcinoma[J].Cancer Epidemiol Biomarkers Prev, 2016, 25 (4) :686-692.
|
|
[38]KAWATA S, YAMASAKI E, NAGASE T, et al.Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma.A randomized controlled trial[J].Br J Cancer, 2001, 84 (7) :886-891.
|
|
[39]GRAF H, JUNGST C, STRAUB G, et al.Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma[J].Digestion, 2008, 78 (1) :34-38.
|
|
[40]SHAO JY, LEE FP, CHANG CL, et al.Statin-based palliative therapy for hepatocellular carcinoma[J].Medicine (Baltimore) , 2015, 94 (42) :e1801.
|
|
[41]CASH WJ, O’NEILL S, O’DONNELL ME, et al.Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis[J].Liver Int, 2013, 33 (8) :1-9.
|
|
[42]BAYS H, COHEN DE, CHALASANI N, et al.An assessment by the statin liver safety task force:2014 up-date[J].J Clin Lipidol, 2014, 8 (3) :s47-s57.
|
|
[43]TIKKANT MJ, FAYYAD R, PAERGEMAN O, et al.Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels[J].Int J Cardiol, 2013, 168 (4) :3846-3852.
|
|
[44]LEWIS JH, MORTENSEN ME, ZWEIG S, et al.Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease:results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial[J].Hepatology, 2007, 46 (5) :1453-1463.
|
|
[45]FORSTER T, BUDOFF MJ, SAAB S, et al.Atorvastatin and ntioxidants for the treatment of nonalcoholic fatty liver disease:the St.Francis Heart Study random-ized clinical trial[J].Am J Gastroenterol, 2011, 106 (1) :71-77.
|
DownLoad: